ArticleClinical kidney journal2026
Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04262934 (Multicenter Randomized Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Randomized Study : Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients?
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many factors contribute to muscle impairment during chronic kidney disease, among which vitamin D deficiency has been implicated. The aim of this study was to analyze whether cholecalciferol supplementation in hemodialysis patients with low 25-hydroxyvitamin vitamin D (25OHD) concentrations could improve handgrip strength (HGS). Methods: VITADIAL (Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in HemoDIALysis Patients?) is a prospective open-labeled French multicenter study in which chronic hemodialysis patients with a 25OHD ≤50 nmol/L were randomized to receive monthly oral 100 000 IU cholecalciferol or no vitamin D treatment during 6 months to assess whether cholecalciferol supplementation in vitamin D-deficient hemodialysis patients improves muscle strength as measured with HGS. The main objective of the study was to analyze whether a 6-month period of oral cholecalciferol improved the muscle strength of hemodialysis patients with low 25OHD levels. Results: Within the 270 hemodialysis patients from 10 hemodialysis centers included in the study, 143 patients with 25OHD ≤50 nmol/L were randomized: 70 were allocated to the cholecalciferol group and 73 to the control group. The two groups were comparable at inclusion. The cholecalciferol supplemented group's 25OHD rose to 89.78 ± 33.43 nmol/L at 6 months and remained ≤50 nmol/L for most patients in the control group, but HGS did not change significantly between randomization and end of the study in both groups (0.07 ± 3.40 kg and -0.19 ± 3.35 kg, respectively, Conclusions: This highly powered study did not find any effect of cholecalciferol supplementation in muscle strength of hemodialysis patients with low 25OHD.Trial registration: ClinicalTrials, NCT04262934. Registered 10 February 2020. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04262934.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.